Holen Sie sich die Stockscreener-App
0.2999
0.20%
0.0006
Handel nachbörslich:
.30
0.000100
+0.03%
Fibrogen Inc Aktie (FGEN) Neueste Nachrichten
FibroGen (FGEN) Receives Reaffirmed Buy Rating from HC Wainwrigh - GuruFocus
FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline - MSN
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ... - Yahoo Finance
FibroGen Inc earnings beat by $0.15, revenue fell short of estimates - Investing.com Nigeria
FibroGen Reports Q1 2025 Earnings and Strategic Updates - TipRanks
FibroGen (FGEN) Boosts Sale Proceeds from Chinese Division - GuruFocus
Earnings call transcript: FibroGen Q1 2025 sees revenue drop, stock rises - Investing.com Canada
FibroGen Q1 2025 Earnings Call Transcript - MarketBeat
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
FibroGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimat - GuruFocus
FibroGen: Q1 Earnings Snapshot - San Antonio Express-News
FIBROGEN INC SEC 10-Q Report - TradingView
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FibroGen (FGEN) Set to Release Q1 Earnings Results - GuruFocus
FibroGen to Report First Quarter 2025 Financial Results - GlobeNewswire
FibroGen Q1 2025 Earnings Call: Key Details for May 12 Financial Results Release - Stock Titan
FibroGen, Inc. to Announce Q1 2025 Financial Results and Host Conference Call on May 12 - Nasdaq
Press Release Distribution & PR Platform - ACCESS Newswire
Investor Network: FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FGEN Stock Price and Chart — NASDAQ:FGEN - TradingView
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
William Blair Keeps Their Hold Rating on FibroGen (FGEN) - The Globe and Mail
FibroGen extends merger option deadline with Fortis - Investing.com Australia
FibroGen extends merger option deadline with Fortis By Investing.com - Investing.com South Africa
Morgan Stanley’s Adam Jonas Is Pounding the Table on This 1 ‘Unique’ Stock - The Globe and Mail
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology - The Manila Times
FibroGen reports promising FG-3246 study results for prostate cancer - Investing.com
1 Top Cryptocurrency to Buy Before It Soars 14,623%, According to Michael Saylor - The Globe and Mail
Fibrogen CEO Wettig Thane buys $50,663 in common stock By Investing.com - Investing.com Australia
Fibrogen CEO Wettig Thane buys $50,663 in common stock - Investing.com India
Fibrogen director James Schoeneck buys $105,040 in stock By Investing.com - Investing.com Canada
Fibrogen director James Schoeneck buys $105,040 in stock - Investing.com
In the Red? AstraZeneca Acquires FibroGen, Inc.’s China Subsidiary - Law Street Media
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):